Share Name Share Symbol Market Type Share ISIN Share Description
Polarean Imaging Plc LSE:POLX London Ordinary Share GB00BF3DT583 ORD GBP0.00037
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 69.00 68.00 70.00 69.00 69.00 69.00 119,042 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.7 -4.6 -4.3 - 144

Polarean Imaging PLC Board appointment

22/02/2021 7:00am

UK Regulatory (RNS & others)

Polarean Imaging (LSE:POLX)
Historical Stock Chart

From Feb 2021 to Apr 2021

Click Here for more Polarean Imaging Charts.


RNS Number : 8077P

Polarean Imaging PLC

22 February 2021

Polarean Imaging Plc

("Polarean" or the "Company")

Board appointment

Polarean Imaging plc (AIM: POLX), the medical--imaging technology company, with a proprietary drug--device combination product using hyperpolarised xenon-129 gas to enhance magnetic resonance imaging (MRI) in pulmonary medicine, announces the appointment of Charles ("Chuck") Fremont Osborne Jr. to the Board with immediate effect.

Chuck joined Polarean in April 2019 as Chief Financial Officer ("CFO"). He was previously at Innocrin Pharmaceuticals Inc ("Innocrin"), a privately held oncology therapeutics company where he was CFO since 2015. Prior to his role at Innocrin, Chuck was CFO of Scynexis Inc, a publicly traded anti-infective company between 2003 and 2015. Chuck holds a Bachelor of Science degree in Business Administration, with a Concentration in Accounting, from University of North Carolina. He is a Certified Public Accountant and began his accounting career at Deloittie & Touche in 1988.

Richard Hullihen, CEO of Polarean Imaging, commented: "Chuck has been an invaluable addition to the team since his appointment in 2019, and this next step to take a position on the Board is a natural one. Chuck has significant capital markets experience coupled with a strong knowledge of financial operations within the pharmaceutical industry, and we welcome him to the Board ahead of the next phase of Polarean's lifecycle."

The following information regarding the appointment of Charles Osborne (aged 55) is required to be disclosed under Rule 17, Schedule 2(g) of the AIM Rules for Companies:

Current directorships/partnerships: None

Directorships and partnerships held within the last five years: None

Shareholding: Charles Osborne holds 1,200,000 options over ordinary shares of the Company.

Save for the information set out above, there are no further disclosures to be made in respect of the appointment of Charles Osborne.


 Polarean Imaging plc                               / 
 Richard Hullihen, Chief Executive                                                  Via Walbrook PR 
  Jonathan Allis, Chairman 
 Stifel Nicolaus Europe Limited (NOMAD and 
  Sole Corporate Broker)                                                        +44 (0)20 7710 7600 
 Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare 
  Investment Banking) 
 Nick Adams / Fred Walsh (Corporate 
 Walbrook PR                                    Tel: +44 (0)20 7933 8780 or 
 Paul McManus / Anna Dunphy                                  Mob: +44 (0)7980 541 893 / +44 (0)7876 
                                                                                            741 001 

About Polarean ( )

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

February 22, 2021 02:00 ET (07:00 GMT)

1 Year Polarean Imaging Chart

1 Year Polarean Imaging Chart

1 Month Polarean Imaging Chart

1 Month Polarean Imaging Chart
ADVFN Advertorial
Your Recent History
Polarean I..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210419 09:36:49